MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-06427878 10 mg
Drug: [11C]PF-06427878
Drug: PF-06427878 600 mg
First Posted Date
2015-04-07
Last Posted Date
2015-10-29
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT02410525
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

🇺🇸

Anylan Center, New Haven, Connecticut, United States

🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2015-04-02
Last Posted Date
2015-08-07
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT02406560
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Placebo
First Posted Date
2015-04-02
Last Posted Date
2016-03-22
Lead Sponsor
Pfizer
Target Recruit Count
22
Registration Number
NCT02407353
Locations
🇺🇸

Glendale Adventist Medical Center, Glendale, California, United States

🇺🇸

California Clinical Trials Medical Group, Inc., Glendale, California, United States

PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects

Phase 4
Terminated
Conditions
Gastroesophageal Reflux Disease
Interventions
First Posted Date
2015-03-27
Last Posted Date
2024-04-09
Lead Sponsor
Pfizer
Target Recruit Count
19
Registration Number
NCT02401035
Locations
🇺🇸

Children's Health Specialty Center Dallas Campus, Dallas, Texas, United States

🇺🇸

Children's Medical Center Dallas, Dallas, Texas, United States

🇺🇸

Primary Children's Hospital, Salt Lake City, Utah, United States

and more 16 locations

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Drug: PF 06260414 solid dose formulation
First Posted Date
2015-03-19
Last Posted Date
2018-11-14
Lead Sponsor
Pfizer
Registration Number
NCT02393807
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Placebo
First Posted Date
2015-03-18
Last Posted Date
2016-03-02
Lead Sponsor
Pfizer
Target Recruit Count
40
Registration Number
NCT02391623
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Phase 2
Terminated
Conditions
Staphylococcal Vaccine
Interventions
Biological: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine
Other: Placebo
First Posted Date
2015-03-13
Last Posted Date
2021-01-05
Lead Sponsor
Pfizer
Target Recruit Count
3450
Registration Number
NCT02388165
Locations
🇺🇸

Anne Arundel Medical Group Orthopedics and Sports Medicine Specialists, Pasadena, Maryland, United States

🇺🇸

Seton Medical Center Williamson, Round Rock, Texas, United States

🇺🇸

The Rothman Institute, Philadelphia, Pennsylvania, United States

and more 289 locations

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Phase 2
Completed
Conditions
Prostate Carcinoma Metastatic to the Bone
Castration Resistant Prostate Cancer
Interventions
First Posted Date
2015-03-10
Last Posted Date
2020-05-05
Lead Sponsor
Pfizer
Target Recruit Count
23
Registration Number
NCT02384382
Locations
🇺🇸

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

Wimr Pet/Ct, Madison, Wisconsin, United States

and more 2 locations

A Rollover Protocol of Dacomitinib For Patients In Japan

Phase 2
Completed
Conditions
NSCLC
Interventions
First Posted Date
2015-03-09
Last Posted Date
2020-07-02
Lead Sponsor
Pfizer
Target Recruit Count
7
Registration Number
NCT02382796
Locations
🇯🇵

Kanazawa University Hospital, Kanazawa City, Ishikawa, Japan

🇯🇵

Kurashiki Central Hospital, Kurashiki, Okayama, Japan

🇯🇵

Osaka City General Hospital Department of Clinical Oncology, Osaka-city, Osaka, Japan

and more 3 locations

Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Biological: etanercept
First Posted Date
2015-03-04
Last Posted Date
2017-05-15
Lead Sponsor
Pfizer
Target Recruit Count
188
Registration Number
NCT02378506
Locations
🇧🇬

UMHAT "Sv. Ivan Rilski" EAD, Sofia, Sofia, Bulgaria

🇧🇬

Medical Center - "New rehabilitation center" EOOD, Stara Zagora, Bulgaria

🇭🇷

Medicinski Centar Kuna Peric, Zagreb, Croatia

and more 27 locations
© Copyright 2025. All Rights Reserved by MedPath